BPG is committed to discovery and dissemination of knowledge
Meta-Analysis Open Access
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 124040
Published online Nov 15, 2026. doi: 10.4251/wjgo.124040
Elevated pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predict poor survival in cholangiocarcinoma: A large-scale meta-analysis of 48 cohorts
Wen-Miao Cai, Wei Jiang, Bao-Feng He, Jun-Jie Yu, Xian-Hua Zeng, Sun Liu, Department of Surgery, First People’s Hospital of Changde City, Changde 410000, Hunan Province, China
Lei Peng, Department of Orthopedics, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510000, Guangdong Province, China
ORCID number: Lei Peng (0000-0001-5406-3259).
Co-first authors: Wen-Miao Cai and Wei Jiang.
Co-corresponding authors: Lei Peng and Sun Liu.
Author contributions: Cai WM, He BF, Yu JJ, Zeng XH, Peng L, and Liu S contributed to manuscript review and editing; Cai WM, Jiang W, Yu JJ, and Zeng XH contributed to supervision; Cai WM, Jiang W, Yu JJ, Zeng XH, and Peng L contributed to methodology; Cai WM contributed to resources, project administration, and conceptualization; Cai WM and Jiang W contributed equally to this manuscript as co-first authors; Cai WM, Jiang W, He BF, and Zeng XH contributed to investigation; Jiang W and Yu JJ contributed to formal analysis; Jiang W contributed to writing of the original draft; Jiang W and Liu S contributed to data curation; Peng L and Liu S contributed equally to this manuscript as co-corresponding authors. All authors have read and approved the final manuscript.
AI contribution statement: The authors used Grammarly solely for English language editing and proofreading of the manuscript. The authors reviewed and edited the AI-generated text and take full responsibility for the content and accuracy of the final publication.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Lei Peng, PhD, Department of Orthopedics, The Third Affiliated Hospital of Southern Medical University, Zhongshan Avenue, Guangzhou 510000, Guangdong Province, China. 1015425249@qq.com
Received: June 4, 2026
Revised: July 16, 2026
Accepted: July 30, 2026
Published online: November 15, 2026
Processing time: 154 Days and 11.5 Hours

Abstract
BACKGROUND

The prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in cholangiocarcinoma (CCA) remains controversial largely due to varying cohort sizes across studies. Because CCA is characterized by marked anatomical heterogeneity, frequent biliary obstruction/cholangitis, and a distinct immunosuppressive microenvironment, the clinical interpretation of inflammatory biomarkers may differ from that in other solid tumors.

AIM

To comprehensively evaluate the prognostic significance of pretreatment NLR and PLR in CCA patients.

METHODS

PubMed, EMBASE, Web of Science, and Cochrane Library were systematically searched up to May 2026. Studies evaluating the association between pretreatment NLR/PLR and overall survival (OS) or disease-free survival in CCA were included. Because cut-off values differed across studies, pooled hazard ratios (HRs) were interpreted as aggregated comparisons between study-defined high and low groups rather than the effect of a single universal threshold. Pooled HRs and 95% confidence intervals (CIs) were calculated.

RESULTS

Based on a large-scale synthesis of 48 retrospective cohorts, elevated pretreatment NLR was significantly associated with poorer OS (pooled HR = 1.31, 95%CI: 1.22-1.41, P < 0.001) and disease-free survival. Similarly, high PLR was correlated with worse OS (HR = 1.14, 95%CI: 1.07-1.22, P < 0.001). Comprehensive subgroup analyses confirmed the prognostic stability of NLR across tumor types (intrahepatic CCA, extrahepatic CCA) and regions. Notably, NLR exerted a more profound negative impact on survival in patients receiving non-surgical/palliative therapies (HR = 1.73, 95%CI: 1.32-2.27) compared to those undergoing curative surgery (HR = 1.33, 95%CI: 1.18-1.50).

CONCLUSION

Elevated pretreatment NLR and PLR may be associated with poor prognosis in CCA. The pronounced impact of NLR in palliative settings highlights its potential value in risk stratification for unresectable patients. However, standardized cut-off values have not yet been established, and further prospective validation is required before these markers can be used as specific clinical decision-making criteria.

Key Words: Cholangiocarcinoma; Neutrophil-to-lymphocyte ratio; Platelet-to-lymphocyte ratio; Prognosis; Meta-analysis

Core Tip: Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio serve as significant prognostic biomarkers for cholangiocarcinoma. This meta-analysis of 48 cohorts confirms that elevated NLR and platelet-to-lymphocyte ratio correlate with poorer overall and disease-free survival. Notably, NLR demonstrates superior predictive value in patients receiving palliative therapy compared to those undergoing curative surgery. These findings suggest that NLR is a valuable tool for risk stratification in unresectable cases. However, the lack of standardized cut-off values necessitates cautious clinical application and further prospective validation before routine implementation.



INTRODUCTION

Cholangiocarcinoma (CCA) is a highly aggressive and heterogeneous group of malignancies arising from the biliary epithelium[1-5]. Based on the anatomical site of origin, CCA is traditionally classified into intrahepatic CCA (iCCA), perihilar CCA (pCCA), and distal CCA (dCCA)[3,6]. Despite advances in surgical techniques, chemotherapy, and targeted immunotherapy, the prognosis for CCA remains dismal, with a 5-year survival rate of less than 10%[7,8]. The poor outcome is largely attributed to late clinical presentation, high recurrence rates, and resistance to conventional therapies. Therefore, identifying reliable, non-invasive, and cost-effective prognostic biomarkers is of paramount importance for optimizing clinical decision-making and improving patient outcomes. Importantly, CCA differs from many other solid tumors in several clinically relevant respects, including frequent biliary obstruction, recurrent cholangitis, impaired liver function, and the need for biliary drainage before definitive treatment. These disease-specific features may substantially influence systemic inflammatory indices and complicate the interpretation of blood-based biomarkers in routine practice.

Increasing evidence suggests that the tumor microenvironment and systemic inflammatory response play a critical role in tumor initiation, progression, angiogenesis, and metastasis[9,10]. In recent years, peripheral blood-based inflammatory indices, such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), have garnered significant attention[11]. Neutrophils can promote tumor growth by secreting vascular endothelial growth factor and matrix metalloproteinases, while lymphocytes are crucial for mediating anti-tumor immune responses. Platelets can shield circulating tumor cells from immune destruction and facilitate distant metastasis. Consequently, an elevated NLR or PLR—reflecting an imbalance favoring pro-tumorigenic inflammation and diminished anti-tumor immunity—has been associated with poor prognosis in multiple solid tumors, including gastric, colorectal, and hepatocellular carcinomas[12,13].

Although several individual studies have investigated the prognostic value of NLR and PLR in CCA, the results have been inconsistent. In addition, the reported cut-off values for NLR and PLR vary considerably across studies, meaning that the same absolute value may be classified as “high” in one cohort but “low” in another. This issue is directly relevant to the interpretation and clinical applicability of pooled prognostic estimates. Furthermore, with the advent of novel systemic therapies and the publication of numerous new retrospective cohorts up to 2025/2026, an updated, large-scale quantitative synthesis is urgently needed. This systematic review and meta-analysis aim to definitively elucidate the prognostic significance of pretreatment NLR and PLR in patients with CCA.

MATERIALS AND METHODS
Literature search strategy

This systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines[14]. A comprehensive literature search was performed in PubMed, EMBASE, Web of Science, and the Cochrane Library for studies published up to May 1, 2026. The search terms included a combination of Medical Subject Headings and free-text words: (“cholangiocarcinoma” OR “biliary tract cancer” OR “bile duct cancer”) AND (“neutrophil-to-lymphocyte ratio” OR “NLR” OR “platelet-to-lymphocyte ratio” OR “PLR” OR “inflammatory markers”) AND (“prognosis” OR “survival” OR “mortality” OR “outcome”).

Inclusion and exclusion criteria

Studies were considered eligible if they met the following inclusion criteria: (1) Patients were pathologically or histologically diagnosed with CCA; (2) Pretreatment NLR or PLR was measured; (3) The association between NLR/PLR and survival outcomes [overall survival (OS) or disease-free survival (DFS)/recurrence-free survival] was evaluated; and (4) Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were provided directly or could be calculated from the available data. The exclusion criteria were: (1) Case reports, reviews, letters, or conference abstracts; (2) Studies with insufficient data to estimate HRs and 95%CIs; (3) Overlapping or duplicate patient cohorts; and (4) Animal or in vitro studies.

Data extraction and quality assessment

Two independent reviewers (Peng L and Cai WM) systematically extracted the following data from the included studies: First author, publication year, country, tumor location (iCCA, pCCA, dCCA), sample size, clinical stage, treatment modalities, cut-off values for NLR/PLR, and HRs with 95%CIs for survival outcomes. Discrepancies were resolved by consensus or by consulting a third investigator (He BF). The methodological quality of the included retrospective studies was systematically assessed using the Newcastle-Ottawa Scale (NOS). The NOS evaluates studies based on three broad perspectives: The selection of the study groups (0-4 points), the comparability of the groups (0-2 points), and the ascertainment of the outcome of interest (0-3 points). A study can be awarded a maximum of 9 points. In this meta-analysis, studies achieving a score of 6 or higher were considered to be of high methodological quality.

Statistical analysis

All statistical analyses were performed using Python (version 3.4, utilizing ‘pandas’ and ‘scipy’ libraries) and Stata 16.0. The prognostic value of NLR and PLR was evaluated using pooled HRs and 95%CIs. Because the original studies adopted different thresholds, the pooled HRs should be interpreted as summary estimates comparing study-defined high vs low NLR/PLR groups rather than the effect of one absolute NLR or PLR value. An HR > 1 indicated a worse prognosis for patients with elevated NLR or PLR. Heterogeneity among the included studies was assessed using the Cochran’s Q test and the I2 statistic. I2 value > 50% or P < 0.10 for the Q test indicated significant heterogeneity, in which case a DerSimonian-Laird random-effects model was employed. Otherwise, a fixed-effects model was used. Potential publication bias was evaluated using Begg’s funnel plots and Egger’s test. A two-sided P < 0.05 was considered statistically significant.

RESULTS
Protocol and registration

This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD420261412298 and was conducted in accordance with the registered protocol. The review was performed following the PRISMA 2009 Statement and adhered to the methodological recommendations of the Cochrane Handbook for Systematic Reviews of Interventions.

Characteristics of the included studies

Based on our rigorous literature search strategy (search strategy in Supplementary material and Supplementary Table 1), a total of 48 studies were included in this meta-analysis (Supplementary Figure 1). Among them, 47 cohorts provided valid data for the NLR analysis, and 29 cohorts for the PLR analysis. The studies were predominantly retrospective in nature and published from 2008 to 2026. The baseline characteristics of the included cohorts, comprising patients from various regions (predominantly Asian populations), encompassed different CCA subtypes including iCCA, pCCA, and dCCA. The sample sizes ranged significantly across studies, and patients underwent various treatment modalities including curative resection and palliative therapies. However, the timing of blood sampling relative to biliary drainage, cholangitis control, or supportive treatment was not uniformly reported, and the handling of patients with active cholangitis was inconsistently described across studies. In addition, Table 1[7,9,11,15-59] summarizes the reported approaches used to derive NLR/PLR cut-offs; however, this information was frequently not reported in the original studies and was therefore recorded as “NR” when unavailable.

Table 1 Characteristics of the included studies.
Ref.
Tumor type
Sample size
Research type
Endpoint
NLR cut-off
PLR cut-off
Cut-off derivation method
Wang et al[15], 2026Distal cholangiocarcinoma208Retrospective cohortOSNRNRNR
Li et al[16], 2025hCCA112Retrospective cohortOS2.98155.47NR
Fukushi et al[17], 2026CCA103Retrospective studyOS5148NR
Matsumoto et al[18], 2026CCA29Retrospective studyPFS5NRNR
Guo et al[11], 2026hCCA373Retrospective studyRFS3.3114.83NR
Chindaprasirt et al[7], 2026CCA213Retrospective studyDFS/OS2.4NRNR
Mii et al[19], 2025CCA54Retrospective studyPFS/OS3NRNR
Ge et al[20], 2022pCCA333Retrospective studyOS/RFS1.68113.1NR
Li et al[21], 2022eCCA140Retrospective studyOS2.66125.82NR
Lin et al[22], 2022pCCA76Retrospective studyOS2NRNR
Yang et al[23], 2022iCCA73Retrospective studyOS3.56222.52NR
Zhang et al[24], 2022iCCA162Retrospective studyOS3.7376.51NR
Catalano et al[25], 2024iCCA758Retrospective studyOS2.57172.5NR
Fu et al[26], 2024pCCA139Retrospective cohort studyOS3.19NRNR
Jin et al[27], 2024CCA120Retrospective cohort studyOS1.08204.62NR
Lang et al[9], 2025iCCA286Retrospective cohort studyOS2.65167.8NR
Zhao et al[28], 2021iCCA468Retrospective cohort studyOS3143.5NR
Ma et al[29], 2021iCCA174Retrospective cohortOS/DFS390NR
Zhang et al[30], 2020iCCA128Retrospective studyOS/DFS3156.8NR
Tsilimigras et al[31], 2020iCCA688Retrospective studyOS5190NR
Ohira et al[32], 2020iCCA52Retrospective studyOS1.9398NR
Ji et al[33], 2020eCCA59Retrospective studyOS2.93268.9NR
Huh et al[34], 2020iCCA137Retrospective studyOS/DFS5148NR
Filippi et al[35], 2020iCCA20Retrospective studyOS2.7NRNR
Zhang et al[36], 2019iCCA322Retrospective studyOS/DFS3NRNR
Wu et al[37], 2019iCCA123Retrospective studyOS2.05157.3NR
Sellers et al[38], 2019iCCA131Retrospective studyOS3.96156.4NR
Lin et al[39], 2019iCCA218Retrospective studyOS2.94130.6NR
Hu et al[40], 2019eCCA134Retrospective studyOS3150NR
Hoshimoto et al[41], 2019eCCA53Retrospective cohort studyOS/DFS1.97187.8NR
Buettner et al[42], 2018iCCA991Retrospective cohort studyOS5190NR
Yoh et al[43], 2017iCCA141Retrospective studyOS5120NR
Omichi et al[44], 2017iCCA119Retrospective studyOS/DFS3NRNR
Nam et al[45], 2017iCCA377Retrospective studyOS2.7NRNR
Kitano et al[46], 2017eCCA120Retrospective studyOS/DFS2.8185NR
Cho et al[47], 2018iCCA305Retrospective studyOS/DFS2.8128.3NR
Okuno et al[48], 2016eCCA219Retrospective studyOS5NRNR
Okuno et al[49], 2016eCCA534Retrospective studyOS3150NR
Lin et al[50], 2016iCCA102Retrospective studyOS/DFS3NRNR
Lee et al[51], 2016CCA221Retrospective studyOS/DFS5NRNR
Ha et al[52], 2016CCA534Retrospective studyOS3.49NRNR
Beal et al[53], 2016eCCA525Retrospective studyOS/DFS5NRNR
Chen et al[54], 2015iCCA322Retrospective studyOS/DFS2.49NRNR
Chen et al[55], 2015iCCA322Retrospective studyOS/DFSNR123NR
McNamara et al[56], 2014CCA864Retrospective studyOS3NRNR
Iwaku et al[57], 2014CCA52Retrospective studyOS4NRNR
Dumitrascu et al[58], 2013eCCA90Retrospective studyOS/DFS3.3NRNR
Gomez et al[59], 2008iCCA27Retrospective studyOS/DFS5NRNR

According to the NOS quality assessment, all included studies scored between 6 points and 9 points, with a median score of 7.5. This indicates that the cohorts incorporated into this meta-analysis are of high methodological quality, thereby lending robust credibility to the pooled analytical results (Supplementary Figure 1).

Prognostic value of pretreatment NLR on OS

A total of 47 studies evaluated the correlation between pretreatment NLR and OS. Because significant heterogeneity was observed (I2 = 77.2%, P < 0.001), a random-effects model was used. The pooled analysis revealed that an elevated NLR was significantly associated with poorer OS in patients with CCA (pooled HR = 1.31, 95%CI: 1.22-1.41, P < 0.001) (Figure 1A).

Figure 1
Figure 1 Prognostic value of pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte on overall survival. A: Prognostic value of pretreatment neutrophil-to-lymphocyte ratio on overall survival; B: Prognostic value of pretreatment platelet-to-lymphocyte ratio on overall survival. HR: Hazard ratio; CI: Confidence interval.
Prognostic value of pretreatment NLR on DFS

In addition to OS, we analyzed the impact of NLR on DFS. Data from 15 included cohorts evaluating DFS demonstrated that elevated pretreatment NLR was also a significant predictor of poorer DFS/recurrence-free survival outcomes in CCA patients. The meta-analysis confirmed a consistent negative prognostic impact, reinforcing the role of NLR in predicting tumor recurrence.

Prognostic value of pretreatment PLR on OS

For PLR, 29 studies provided available survival data. The random-effects model was applied due to substantial inter-study heterogeneity (I2 = 69.2%, P < 0.001). The meta-analysis indicated that a high pretreatment PLR was a significant predictor of inferior OS in CCA (pooled HR = 1.14, 95%CI: 1.07-1.22, P < 0.001) (Figure 1B).

Prognostic value of pretreatment PLR on DFS

Further analysis of 8 cohorts providing DFS data for PLR was conducted. The results indicated that an elevated PLR was similarly associated with a significantly shorter DFS time, further validating its utility as a robust prognostic biomarker for disease progression.

Subgroup analysis

To further explore the potential sources of heterogeneity and validate the prognostic value of NLR across different clinical contexts, comprehensive subgroup analyses for OS were performed based on tumor type, geographic region, and treatment modality. A summary of these findings is visually presented in the subgroup forest plot (Figure 2). Because treatment regimens and standards of care for biliary tract malignancies have evolved substantially since the 2010s, particularly with gemcitabine-cisplatin-based chemotherapy and, more recently, immune checkpoint inhibitor-containing regimens, treatment era is also likely to have contributed to between-study heterogeneity; however, regimen-level data were insufficiently consistent across studies to support a reliable pooled era-based analysis.

Figure 2
Figure 2 Subgroup analysis for overall survival based on neutrophil-to-lymphocyte ratio. iCCA: Intrahepatic cholangiocarcinoma; eCCA: Extrahepatic cholangiocarcinoma; CCA: Cholangiocarcinoma; HR: Hazard ratio; CI: Confidence interval.

Tumor type: The prognostic significance of elevated NLR for poor OS was consistently observed across different anatomical subtypes. For iCCA (n = 19), the pooled HR was 1.35 (95%CI: 1.20-1.52, P < 0.001, I2 = 77.2%). For extrahepatic CCA (eCCA, n = 7), the pooled HR was 1.51 (95%CI: 0.86-2.65, P = 0.149, I2 = 83.4%). The mixed CCA subgroup (n = 3) also showed significant association (HR = 1.83, 95%CI: 1.37-2.44, P < 0.001, I2 = 0.0%).

Geographic region: When stratified by patient region, both Asian (n = 22; HR = 1.35, 95%CI: 1.20-1.53, P < 0.001, I2 = 79.8%) and non-Asian cohorts (n = 5; HR = 1.67, 95%CI: 1.36-2.05, P < 0.001, I2 = 0.0%) demonstrated a statistically significant association between high NLR and decreased OS, suggesting that the prognostic value is independent of ethnic or geographic background.

Treatment modality: Subgroup analysis based on treatment revealed that elevated inflammatory markers were predictive of poor survival outcomes regardless of whether patients underwent curative surgery (n = 20; HR = 1.33, 95%CI: 1.18-1.50, P < 0.001, I2 = 79.7%) or received non-surgical/palliative treatments (n = 8; HR = 1.73, 95%CI: 1.32-2.27, P < 0.001, I2 = 44.6%).

Publication period: To account for potential treatment-era effects, an additional subgroup analysis stratified by publication period was performed. The association between elevated NLR and poor OS remained significant in studies published during 2014-2019 (n = 22; HR = 1.56, 95%CI: 1.32-1.84, P < 0.001, I2 = 76.6%) and 2020-2026 (n = 23; HR = 1.34, 95%CI: 1.15-1.57, P < 0.001, I2 = 78.8%). In contrast, the earliest period (≤ 2013) included only two cohorts and did not show a statistically significant association (n = 2; HR = 1.01, 95%CI: 0.99-1.04, P = 0.363, I2 = 0.0%).

Cut-off value: The adverse prognostic impact of high NLR and PLR remained robust across different threshold categories, further reinforcing their independent prognostic value (Figure 2).

Sensitivity analysis

To evaluate the stability and reliability of our pooled results, a sensitivity analysis was performed by sequentially omitting one study at a time (leave-one-out analysis). The omission of any single study did not significantly alter the pooled HRs for either NLR or PLR, indicating that our findings are robust and not driven by any individual study outlier (Supplementary Figures 2 and 3).

Publication bias

Potential publication bias was assessed using Begg’s funnel plots and Egger’s tests. The visual inspection of the funnel plots revealed a generally symmetrical distribution of the included studies. Furthermore, the quantitative Egger’s tests for both NLR and PLR analyses indicated no significant publication bias (all P > 0.05), reinforcing the credibility of the meta-analysis results (Supplementary Figures 4 and 5).

DISCUSSION

CCA is characterized by an immunosuppressive tumor microenvironment and intense desmoplastic stroma, making systemic inflammation a key driver of its biological aggressiveness[60,61]. In this updated meta-analysis encompassing recent cohorts up to 2026, we confirmed that both elevated pretreatment NLR and PLR are significantly associated with poorer OS in CCA patients. Specifically, a high NLR increased the risk of mortality by 31%, while a high PLR increased the risk by 14%.

The prognostic capabilities of NLR and PLR are deeply rooted in tumor immunology. Neutrophils can promote a pro-tumorigenic environment by releasing reactive oxygen species, vascular endothelial growth factor, and matrix metalloproteinases, which facilitate extracellular matrix degradation and tumor angiogenesis. Furthermore, neutrophils can suppress the cytolytic activity of lymphocytes, specifically CD8+ T cells and natural killer cells. Consequently, relative lymphopenia indicates a weakened host anti-tumor immune response, allowing tumor cells to escape immune surveillance.

Similarly, platelets play a multifaceted role in tumor metastasis. Tumor-educated platelets can coat circulating tumor cells, shielding them from shear stress and immune-mediated clearance. Platelets also release transforming growth factor-beta and platelet-derived growth factor, promoting epithelial-mesenchymal transition and extravasation. Therefore, an elevated PLR reflects a hypercoagulable and highly inflammatory state that strongly favors tumor progression.

Our study has several clinical implications. NLR and PLR are derived from routine complete blood counts, making them highly cost-effective, universally accessible, and non-invasive. They can be dynamically monitored throughout the treatment course. Integrating these inflammatory markers into standard prognostic nomograms could improve risk stratification, helping clinicians identify high-risk patients who might benefit from more aggressive adjuvant therapies, closer surveillance, or novel immunotherapeutic approaches. At the same time, these indices should be interpreted as adjunctive rather than stand-alone biomarkers, because prognosis in CCA is also strongly influenced by age, performance status, tumor stage, metastatic burden, liver function, biliary drainage status, and the presence or absence of cholangitis.

Importantly, our comprehensive subgroup analyses offer deeper insights into the clinical utility of NLR. We observed that the prognostic value of NLR was particularly pronounced in patients receiving non-surgical or palliative treatments (HR = 1.73) compared to those undergoing curative surgery (HR = 1.33). Furthermore, the heterogeneity within the palliative subgroup was notably reduced (I2 = 44.6%). This suggests that in advanced-stage CCA patients with higher tumor burdens, the systemic inflammatory response driven by the tumor is more intense and plays a more dominant role in driving disease progression and mortality. Therefore, baseline inflammatory markers might be particularly crucial for risk-stratifying unresectable patients and guiding the timely introduction of systemic therapies or immune checkpoint inhibitors.

Despite the robust findings, several limitations must be acknowledged. First, significant heterogeneity was observed in both the overall NLR and PLR analyses. While our subgroup analysis revealed that treatment modality partially accounts for this heterogeneity, other factors such as diverse cut-off values and institutional variations likely contribute. Second, when stratified by tumor location, although high NLR was a strong predictor of poor OS in iCCA, it did not reach statistical significance in eCCA (P = 0.149). This lack of significance is likely attributed to the limited number of studies (n = 7) and high inter-study heterogeneity (I2 = 83.4%) in the eCCA subgroup, rather than a lack of biological effect. Third, the timing of NLR and PLR measurement is clinically important in CCA, because values obtained during active cholangitis or biliary obstruction may reflect infection-related inflammation rather than tumor biology alone. From a practical standpoint, measurement after biliary drainage and after resolution of overt cholangitis, or immediately before definitive anti-cancer treatment, may provide more clinically meaningful information, although this requires prospective validation. Fourth, treatment strategies for CCA have evolved considerably over time, and the transition from earlier chemotherapy-only eras to contemporary immune checkpoint inhibitor-containing regimens may also have influenced survival outcomes. Most of the included studies were retrospective in design, which carries an inherent risk of selection bias. Future large-scale, prospective, multi-center studies with standardized cut-off values, specifically focusing on the eCCA population and varied treatment lines, are warranted to validate these results.

CONCLUSION

In conclusion, elevated pretreatment NLR and PLR may be associated with poor prognosis in patients with CCA. However, standardized cut-off values have not yet been established, and further prospective studies are required before these markers can be used as specific clinical decision-making criteria.

References
1.  Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168-2179.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1509]  [Cited by in RCA: 1511]  [Article Influence: 125.9]  [Reference Citation Analysis (13)]
2.  Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428-444.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 871]  [Cited by in RCA: 845]  [Article Influence: 169.0]  [Reference Citation Analysis (9)]
3.  Banales JM, Rodrigues PM, Affò S, Andersen JB, Aspichueta P, Boulter L, Bridgewater J, Calvisi DF, Cardenas A, Cardinale V, Carpino G, Coulouarn C, Dopazo C, Edeline J, Fabris L, Folseraas T, Forner A, Goeppert B, Heikenwalder M, Kendall TJ, Khan SA, Klümpen HJ, Koerkamp BG, Lamarca A, Lindsey S, Lleo A, Luedde T, Macias RIR, Morement H, Nault JC, Olaizola P, Perugorria MJ, Raggi C, Rimassa L, Saborowski A, Valle JW, Vithayathil M, Vogel A, Braconi C; International CCA Consensus Consortium. Cholangiocarcinoma 2026: status quo, unmet needs and priorities. Nat Rev Gastroenterol Hepatol. 2026;23:65-96.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 7]  [Cited by in RCA: 59]  [Article Influence: 59.0]  [Reference Citation Analysis (6)]
4.  Liu F, Chen W, Zhang Z, Zeng W, Hu H, Ning S, Liao Z, Liu Y, Zhang H, Fu Q, Zhang B, Chen X, Zhang W, Zhang Z. Targeting Aurora kinase B regulates cholesterol metabolism and enhances chemoimmunotherapy in cholangiocarcinoma. Gut. 2026;75:353-366.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 14]  [Cited by in RCA: 16]  [Article Influence: 16.0]  [Reference Citation Analysis (0)]
5.  Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol. 2025;51:107064.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 136]  [Cited by in RCA: 126]  [Article Influence: 126.0]  [Reference Citation Analysis (2)]
6.  Li C, Zhang N, Ren H. Nutritional-Inflammatory Recovery After Metal versus Plastic Biliary Stenting in Elderly Cholangiocarcinoma: A Prospective Observational Cohort Study. Clin Interv Aging. 2026;21:593418.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
7.  Chindaprasirt J, Sanlung T, Watcharenwong P, Thanasukarn V, Jareanrat A, Khuntikeo N, Srisuk T, Sa-Ngiamwibool P, Aphivatanasiri C, Loilome W, Prajumwongs P, Titapun A. Preoperative Prognostic Score for Patients with Intrahepatic Cholangiocarcinoma Undergoing Curative-Intent Resection. Med Sci (Basel). 2026;14:23.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 1]  [Reference Citation Analysis (2)]
8.  Alidina Z, Banani I, Abiha UE, Sultan U, Pawlik TM. Radiomics for Detection and Differentiation of Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2026;18:937.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
9.  Lang SQ, Kong JJ, Li GB, Liu J. Prognostic value of CRP-albumin-lymphocyte index in patients with intrahepatic cholangiocarcinoma after radical resection. Front Med (Lausanne). 2025;12:1543665.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 12]  [Reference Citation Analysis (0)]
10.  Shi W, Jin W, Hong L, Wu H, Hu S. Clinical value of blood routine and tumor markers in differentiating hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Medicine (Baltimore). 2025;104:e41899.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 3]  [Reference Citation Analysis (0)]
11.  Guo H, Bai X, Shi J, Liu Z, Hu Z. The prognostic value analysis of PIV, PLR, LMR, NPR, and NLR in hilar cholangiocarcinoma. BMC Cancer. 2026;26:437.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1]  [Cited by in RCA: 1]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
12.  Utsumi M, Inagaki M, Kitada K, Tokunaga N, Yonoki K, Sakurai Y, Okabayashi H, Hamano R, Miyasou H, Tsunemitsu Y, Otsuka S. Prognostic Significance of Sarcopenia and Systemic Inflammatory Markers in Biliary Tract Cancer: A Retrospective Cohort Study. J Gastrointest Cancer. 2024;55:888-899.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 8]  [Reference Citation Analysis (0)]
13.  Qi S, Ma Z, Shen L, Wang J, Zhou L, Tian B, Liu C, Chen K, Cheng W. Application of preoperative NLR-based prognostic model in predicting prognosis of intrahepatic cholangiocarcinoma following radical surgery. Front Nutr. 2024;11:1492358.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 4]  [Reference Citation Analysis (0)]
14.  Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777-784.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 6559]  [Cited by in RCA: 6481]  [Article Influence: 589.2]  [Reference Citation Analysis (20)]
15.  Wang F, Li J, Zhao X, Lyu S, He Q. Combined Model of Inflammatory-Nutritional Indicators and Tumor Markers for Predicting Prognosis in Patients with Distal Cholangiocarcinoma: A Retrospective Cohort Study. Diseases. 2026;14:97.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
16.  Li G, He T, Geng M, Qi F. Prognostic significance of the preoperative lactate dehydrogenase-to-albumin ratio in patients undergoing radical resection for hilar cholangiocarcinoma. Front Med (Lausanne). 2025;12:1705110.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
17.  Fukushi Y, Fujita K, Akamine Y, Igarashi H, Sasaki K, Fukuda K, Shibata H, Kikuchi M. Relationship of nutritional or systemic inflammatory markers with efficacy of gemcitabine and cisplatin with or without durvalumab therapy for patients with unresectable or metastatic biliary tract cancer: a retrospective study. J Pharm Health Care Sci. 2026;12:33.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
18.  Matsumoto M, Itoh S, Tsunematsu M, Yugawa K, Furukawa K, Haruki K, Shirai Y, Taniai T, Yanagaki M, Hamura R, Uwagawa T, Okui N, Tanji Y, Akaoka M, Yoshizumi T, Ikegami T. Impact of thyroid-stimulating hormone ratio change on the progression-free survival of patients receiving gemcitabine, cisplatin, and durvalumab therapy for advanced biliary tract cancer. Surg Today. 2026;56:1158-1168.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
19.  Mii S, Kato H, Takahara T, Kojima M, Kato Y, Morise Z, Horiguchi A, Suda K. Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab. World J Surg Oncol. 2025;23:258.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 5]  [Cited by in RCA: 6]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
20.  Ge MY, Liu ZP, Pan Y, Wang JY, Wang X, Dai HS, Gao SY, Zhong SY, Che XY, Zuo JH, Liu YH, Liu XC, Fan HN, Chen WY, Wang ZR, Yin XY, Bai J, Zhang YQ, Jiang Y, Gong Y, Chen ZY. Assessment of the prognostic value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in perihilar cholangiocarcinoma patients following curative resection: A multicenter study of 333 patients. Front Oncol. 2022;12:1104810.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 13]  [Reference Citation Analysis (2)]
21.  Li S, Zhang X, Lou C, Gu Y, Zhao J. Preoperative peripheral blood inflammatory markers especially the fibrinogen-to-lymphocyte ratio and novel FLR-N score predict the prognosis of patients with early-stage resectable extrahepatic cholangiocarcinoma. Front Oncol. 2022;12:1003845.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 9]  [Cited by in RCA: 10]  [Article Influence: 2.5]  [Reference Citation Analysis (2)]
22.  Lin ZQ, Ma C, Cao WZ, Ning Z, Tan G. Prognostic Significance of NLR, PLR, LMR and Tumor Infiltrating T Lymphocytes in Patients Undergoing Surgical Resection for Hilar Cholangiocarcinoma. Front Oncol. 2022;12:908907.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2]  [Cited by in RCA: 24]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
23.  Yang Z, Zhang D, Zeng H, Fu Y, Hu Z, Pan Y, Chen J, Wang J, Zhang Y, Zhou Z, Xu L, Hu D, Chen M. Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma. J Inflamm Res. 2022;15:5721-5731.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 24]  [Cited by in RCA: 26]  [Article Influence: 6.5]  [Reference Citation Analysis (0)]
24.  Zhang D, Zeng H, Pan Y, Zhao Y, Wang X, Chen J, Wang J, Zhang Y, Zhou Z, Xu L, Chen M, Hu D. Liver Tumor Markers, HALP Score, and NLR: Simple, Cost-Effective, Easily Accessible Indexes for Predicting Prognosis in ICC Patients after Surgery. J Pers Med. 2022;12:2041.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 24]  [Cited by in RCA: 24]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
25.  Catalano G, Alaimo L, Chatzipanagiotou OP, Ruzzenente A, Aucejo F, Marques HP, Lam V, Hugh T, Bhimani N, Maithel SK, Kitago M, Endo I, Martel G, Pulitano C, Shen F, Popescu I, Koerkamp BG, Bauer TW, Cauchy F, Poultsides GA, Weiss M, Gleisner A, Pawlik TM. Prognostic value of the advanced lung cancer inflammation index in intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2024;50:108773.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 4]  [Cited by in RCA: 4]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
26.  Fu S, Li J, Fan H, Zheng K, Leng B, Cao G, Xu L, Zhong Y, Niu C, Wang X. NLCECA score: a serum inflammatory-tumor biomarker score to predict survival of advanced perihilar cholangiocarcinoma after hepatic arterial infusion chemotherapy. Sci Rep. 2024;14:4466.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 6]  [Reference Citation Analysis (0)]
27.  Jin J, Mou H, Zhou Y, Zhang S. Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers. Cancer Control. 2024;31:10732748241305237.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 6]  [Reference Citation Analysis (0)]
28.  Zhao J, Chen Y, Wang J, Wang J, Wang Y, Chai S, Zhang Y, Chen X, Zhang W. Preoperative risk grade predicts the long-term prognosis of intrahepatic cholangiocarcinoma: a retrospective cohort analysis. BMC Surg. 2021;21:113.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 9]  [Cited by in RCA: 13]  [Article Influence: 2.6]  [Reference Citation Analysis (2)]
29.  Ma B, Meng H, Shen A, Ma Y, Zhao D, Liu G, Zheng S, Tian Y, Zhang W, Li Q, Li S. Prognostic Value of Inflammatory and Tumour Markers in Small-Duct Subtype Intrahepatic Cholangiocarcinoma after Curative-Intent Resection. Gastroenterol Res Pract. 2021;2021:6616062.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2]  [Cited by in RCA: 16]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
30.  Zhang Z, Zhou Y, Hu K, Huang Y. Investigating effects of preoperative inflammatory biomarkers on predicting survival outcomes of intrahepatic cholangiocarcinoma after curative resection. World J Surg Oncol. 2020;18:272.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 11]  [Cited by in RCA: 25]  [Article Influence: 4.2]  [Reference Citation Analysis (0)]
31.  Tsilimigras DI, Moris D, Mehta R, Paredes AZ, Sahara K, Guglielmi A, Aldrighetti L, Weiss M, Bauer TW, Alexandrescu S, Poultsides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Soubrane O, Koerkamp BG, Endo I, Pawlik TM. The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. HPB (Oxford). 2020;22:1667-1674.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 39]  [Cited by in RCA: 66]  [Article Influence: 11.0]  [Reference Citation Analysis (2)]
32.  Ohira M, Yoshizumi T, Yugawa K, Kosai-Fujimoto Y, Inokuchi S, Motomura T, Mano Y, Toshima T, Itoh S, Harada N, Ikegami T, Soejima Y, Taketomi A, Mori M. Association of inflammatory biomarkers with long-term outcomes after curative surgery for mass-forming intrahepatic cholangiocarcinoma. Surg Today. 2020;50:379-388.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 17]  [Cited by in RCA: 23]  [Article Influence: 3.3]  [Reference Citation Analysis (1)]
33.  Ji F, Kang Q, Wang L, Liu L, Ke Y, Zhu Y, Zhang N, Xiong S, Li Y, Zou H. Prognostic significance of the neutrophil-to-lymphocyte ratio with distal cholangiocarcinoma patients. Medicine (Baltimore). 2020;99:e22827.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 9]  [Cited by in RCA: 14]  [Article Influence: 2.3]  [Reference Citation Analysis (1)]
34.  Huh G, Ryu JK, Chun JW, Kim JS, Park N, Cho IR, Paik WH, Lee SH, Kim YT. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin. BMC Cancer. 2020;20:907.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 9]  [Cited by in RCA: 21]  [Article Influence: 3.5]  [Reference Citation Analysis (1)]
35.  Filippi L, Di Costanzo GG, Tortora R, Pelle G, Saltarelli A, Marino Marsilia G, Cianni R, Schillaci O, Bagni O. Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization. Nucl Med Commun. 2020;41:78-86.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 15]  [Cited by in RCA: 28]  [Article Influence: 4.7]  [Reference Citation Analysis (0)]
36.  Zhang Y, Shi SM, Yang H, Yang LX, Wang Z, Li XD, Yin D, Shi YH, Cao Y, Dai Z, Zhou J, Chen Q. Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection. J Cancer. 2019;10:494-503.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 33]  [Cited by in RCA: 36]  [Article Influence: 5.1]  [Reference Citation Analysis (1)]
37.  Wu Y, Ren F, Chai Y, Xue Z, Shen C, Zhang X, Lv Y, Hu L. Prognostic value of inflammation-based indexes for intrahepatic cholangiocarcinoma following curative resection. Oncol Lett. 2019;17:165-174.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 14]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
38.  Sellers CM, Uhlig J, Ludwig JM, Stein SM, Kim HS. Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease. Cancer Med. 2019;8:5916-5929.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 30]  [Cited by in RCA: 29]  [Article Influence: 4.1]  [Reference Citation Analysis (2)]
39.  Lin J, Fang T, Zhu M, Xu X, Zhang J, Zheng S, Jing C, Zhang M, Liu B, Zhang B. Comparative performance of inflammation-based prognostic scores in patients operated for intrahepatic cholangiocarcinoma. Cancer Manag Res. 2019;11:9107-9119.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 17]  [Cited by in RCA: 25]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
40.  Hu HJ, Jin YW, Zhou RX, Ma WJ, Yang Q, Wang JK, Liu F, Cheng NS, Li FY. Clinical Value of Inflammation-Based Prognostic Scores to Predict the Resectability of Hyperbilirubinemia Patients with Potentially Resectable Hilar Cholangiocarcinoma. J Gastrointest Surg. 2019;23:510-517.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 12]  [Cited by in RCA: 18]  [Article Influence: 2.6]  [Reference Citation Analysis (1)]
41.  Hoshimoto S, Hishinuma S, Shirakawa H, Tomikawa M, Ozawa I, Ogata Y. Association of Preoperative Platelet-to-Lymphocyte Ratio with Poor Outcome in Patients with Distal Cholangiocarcinoma. Oncology. 2019;96:290-298.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 12]  [Cited by in RCA: 20]  [Article Influence: 2.9]  [Reference Citation Analysis (2)]
42.  Buettner S, Spolverato G, Kimbrough CW, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, Gamblin TC, Maithel SK, Pulitano C, Weiss M, Bauer TW, Shen F, Poultsides GA, Marsh JW, IJzermans JNM, Koerkamp BG, Pawlik TM. The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma. Surgery. 2018;164:411-418.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 47]  [Cited by in RCA: 51]  [Article Influence: 6.4]  [Reference Citation Analysis (5)]
43.  Yoh T, Seo S, Hatano E, Taura K, Fuji H, Ikeno Y, Okuda Y, Yasuchika K, Kaido T, Okajima H, Uemoto S. A Novel Biomarker-Based Preoperative Prognostic Grading System for Predicting Survival After Surgery for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2017;24:1351-1357.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 21]  [Cited by in RCA: 25]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
44.  Omichi K, Cloyd JM, Yamashita S, Tzeng CD, Conrad C, Chun YS, Aloia TA, Vauthey JN. Neutrophil-to-lymphocyte ratio predicts prognosis after neoadjuvant chemotherapy and resection of intrahepatic cholangiocarcinoma. Surgery. 2017;162:752-765.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 40]  [Cited by in RCA: 41]  [Article Influence: 4.6]  [Reference Citation Analysis (1)]
45.  Nam K, Hwang DW, Shim JH, Song TJ, Lee SS, Seo DW, Lee SK, Kim MH, Kim KH, Hwang S, Park KM, Lee YJ, Han M, Park DH. Novel Preoperative Nomogram for Prediction of Futile Resection in Patients Undergoing Exploration for Potentially Resectable Intrahepatic Cholangiocarcinoma. Sci Rep. 2017;7:42954.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 7]  [Cited by in RCA: 22]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
46.  Kitano Y, Yamashita YI, Yamamura K, Arima K, Kaida T, Miyata T, Nakagawa S, Mima K, Imai K, Hashimoto D, Chikamoto A, Baba H. Effects of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios on Survival in Patients with Extrahepatic Cholangiocarcinoma. Anticancer Res. 2017;37:3229-3237.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 9]  [Cited by in RCA: 28]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
47.  Cho H, Yoo C, Kim KP, Jeong JH, Kang J, Chang HM, Lee SS, Park DH, Song TJ, Lee SK, Kim MH, Lee HC, Lim YS, Kim KM, Shim JH, Hwang S, Song GW, Moon DB, Lee JH, Lee YJ, Ryoo BY. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. Invest New Drugs. 2018;36:496-502.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 6]  [Cited by in RCA: 10]  [Article Influence: 1.1]  [Reference Citation Analysis (4)]
48.  Okuno M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Evaluation of inflammation-based prognostic scores in patients undergoing hepatobiliary resection for perihilar cholangiocarcinoma. J Gastroenterol. 2016;51:153-161.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 31]  [Cited by in RCA: 37]  [Article Influence: 3.7]  [Reference Citation Analysis (0)]
49.  Okuno M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Appraisal of inflammation-based prognostic scores in patients with unresectable perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2016;23:636-642.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 7]  [Cited by in RCA: 19]  [Article Influence: 1.9]  [Reference Citation Analysis (1)]
50.  Lin G, Liu Y, Li S, Mao Y, Wang J, Shuang Z, Chen J, Li S. Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma. Oncotarget. 2016;7:50963-50971.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 43]  [Cited by in RCA: 72]  [Article Influence: 9.0]  [Reference Citation Analysis (0)]
51.  Lee BS, Lee SH, Son JH, Jang DK, Chung KH, Lee YS, Paik WH, Ryu JK, Kim YT. Neutrophil-lymphocyte ratio predicts survival in patients with advanced cholangiocarcinoma on chemotherapy. Cancer Immunol Immunother. 2016;65:141-150.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 21]  [Cited by in RCA: 28]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
52.  Ha H, Nam AR, Bang JH, Park JE, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ, Oh DY. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget. 2016;7:76604-76612.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 81]  [Cited by in RCA: 87]  [Article Influence: 8.7]  [Reference Citation Analysis (0)]
53.  Beal EW, Wei L, Ethun CG, Black SM, Dillhoff M, Salem A, Weber SM, Tran T, Poultsides G, Son AY, Hatzaras I, Jin L, Fields RC, Buettner S, Pawlik TM, Scoggins C, Martin RC, Isom CA, Idrees K, Mogal HD, Shen P, Maithel SK, Schmidt CR. Elevated NLR in gallbladder cancer and cholangiocarcinoma - making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. HPB (Oxford). 2016;18:950-957.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 34]  [Cited by in RCA: 54]  [Article Influence: 5.4]  [Reference Citation Analysis (1)]
54.  Chen Q, Yang LX, Li XD, Yin D, Shi SM, Chen EB, Yu L, Zhou ZJ, Zhou SL, Shi YH, Fan J, Zhou J, Dai Z. The elevated preoperative neutrophil-to-lymphocyte ratio predicts poor prognosis in intrahepatic cholangiocarcinoma patients undergoing hepatectomy. Tumour Biol. 2015;36:5283-5289.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 53]  [Cited by in RCA: 55]  [Article Influence: 5.0]  [Reference Citation Analysis (1)]
55.  Chen Q, Dai Z, Yin D, Yang LX, Wang Z, Xiao YS, Fan J, Zhou J. Negative impact of preoperative platelet-lymphocyte ratio on outcome after hepatic resection for intrahepatic cholangiocarcinoma. Medicine (Baltimore). 2015;94:e574.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 59]  [Cited by in RCA: 61]  [Article Influence: 5.5]  [Reference Citation Analysis (5)]
56.  McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, Min T, Amir E, Knox JJ. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014;50:1581-1589.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 119]  [Cited by in RCA: 129]  [Article Influence: 10.8]  [Reference Citation Analysis (5)]
57.  Iwaku A, Kinoshita A, Onoda H, Fushiya N, Nishino H, Matsushima M, Tajiri H. The Glasgow Prognostic Score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection. Med Oncol. 2014;31:787.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 14]  [Cited by in RCA: 17]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
58.  Dumitrascu T, Chirita D, Ionescu M, Popescu I. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg. 2013;17:913-924.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 63]  [Cited by in RCA: 62]  [Article Influence: 4.8]  [Reference Citation Analysis (2)]
59.  Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol. 2008;97:513-518.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 135]  [Cited by in RCA: 141]  [Article Influence: 7.8]  [Reference Citation Analysis (1)]
60.  Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, Schwartz ME, Finn RS, Seong J, Wang XW, Paradis V, Abou-Alfa GK, Rimassa L, Kao JH, Zhang BH, Llovet JM, Bruix J, Yip TC, Wong VW, Wong GL, Chan LL, Liu MQ, Gao Q, Shen F, Kelley RK, Cheng AL, Kurosaki M, Toyoda H, Chen WX, Murakami T, Liang P, Zucman-Rossi J, Minami Y, Miyayama S, Wang K, Man K, Hasegawa K, Li Q, Tsuchiya K, Xu L, Chew V, Chow P, Hoshida Y, Lujambio A, Ng IO, Sakamoto M, Park YN, Yau T, Kudo M, Fan J, Zhou J. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Lancet. 2025;406:731-778.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 225]  [Cited by in RCA: 150]  [Article Influence: 150.0]  [Reference Citation Analysis (2)]
61.  Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853-1865.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 857]  [Cited by in RCA: 896]  [Article Influence: 298.7]  [Reference Citation Analysis (4)]
Footnotes

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Oncology

Country of origin: China

Peer-review report’s classification

Scientific quality: Grade C

Novelty: Grade C

Creativity or innovation: Grade C

Scientific significance: Grade C

P-Reviewer: Nishida T, MD, PhD, Japan S-Editor: Hu XY L-Editor: Wang TQ P-Editor: Wang WB

Write to the Help Desk